Biography

Martin Dewhurst was appointed to the Board of Directors as an independent director, and as a member of both the Audit Committee and Compensation Committee in September 2026.
Martin Dewhurst has over 30 years of experience across biotech, biopharma, medical devices, health tech, and healthcare investment. Previously, he spent more than three decades at McKinsey & Company, where he co-led McKinsey’s Global Life Sciences Practice for seven years, doubling its scale and impact while innovating client services in digital and analytics. He also co-founded and co-led the McKinsey Health Institute, and led McKinsey’s Organization Practice in EMEA, with a focus on human capital, transformation, and post-merger integration. Earlier in his career, he worked with Arthur Andersen & Co. and BP Solar International.
Mr. Dewhurst currently serves on the boards of Swixx BioPharma AG, Turn Therapeutics Inc. (Nasdaq: TTRX), Unilabs SA, Cytovation ASA, and Distalmotion SA, where he chairs the Audit Committee. He is also a member of the Remuneration Committee at Cytovation ASA. Previously, he served as Chair of the Advisory Board of MedGenome Labs Ltd. Mr. Dewhurst also serves as a Senior Advisor to Revival Healthcare Capital, PJT Partners’ Life Sciences practice, and Lightrock. 
Mr. Dewhurst received an M.B.A. from INSEAD, where he was named to the Dean’s List, and a B.A. from Magdalen College, Oxford.